Hong Kong, China -- (SBWIRE) -- 12/07/2017 -- Novogen Ltd, an Australian oncology drug development company, announces today that it has entered into a Letter of Intent with Cedrus Investments Ltd for advisory services in order to establish a corporate structure focused on expansion into the Greater China region.

Key Points

- Following initial face-to-face discussions with third parties in China, Novogen has signed Letter of Intent with Cedrus Investments, a leading specialist investment bank based in Hong Kong, for advisory services in order to establish a corporate structure and operations in the People's Republic of China

- Novogen entity will be a Wholly Foreign Owned Enterprise (WFOE), initially with minimal infrastructure, to serve as administrative unit for China expansion

- Key objective will be to further explore partnerships and commercialization opportunities in China over a medium- to long-term horizon

- China is the world's second-largest pharmaceutical market, with approximately US$116.7 billion in annual sales, and an annual growth rate of 12.4% (per QuintilesIMS Market Prognosis, October 2016)

The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials of its pipeline in China, and will facilitate potential partnering and investing opportunities for the company.

The Letter of Intent defines the key terms of the proposed establishment, with most of the work expected to be conducted in the first half of calendar 2018, subject to execution of definitive agreements. It is expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.

Novogen CEO, Dr. James Garner, commented, "China is a key market for pharmaceutical companies, and over the last few months we have been actively exploring opportunities to engage with Chinese companies, researchers, and investors to support the development of Novogen's current and future pipeline there. The team at Cedrus Investments have been helping global companies best position themselves to identify and work with investors and business partners in the Greater China region, and are highly experienced in navigating the complex regulatory requirements in China. We are pleased to be working with them on this important project. The new corporate structure will put us in a stronger position to capitalize on opportunities in China over the medium term."

In addition to its Australian operations and the intended China operation, Novogen also has a US-based corporate entity, Novogen North America, Inc.

About Novogen Limited
Novogen Limited is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best- in-class agents in a range of oncology indications.

The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. A second clinical program, TRX-E-002-01 (Cantrixil) commenced a phase I clinical trial in ovarian cancer in December 2016. In addition, the company has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.

For more information, please visit: http://www.novogen.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Chairman of Cedrus Investments, Mr. Rani Jarkas, is invited to speak at the Mines and Money Asia 2017 conference to be held on 5th – 7th April 2017 in Hong Kong.

Hong Kong, China -- (SBWIRE) -- 12/05/2017 -- The Chairman of Cedrus Investments ("Cedrus"), Mr. Rani Jarkas, is invited to speak at the Mines and Money Asia 2017 conference to be held on 5th – 7th April 2017 in Hong Kong. This year, the conference will be featuring the inaugural of "Future Energy and Finance Asia – Funding the Future". Event participants will include senior management from hundreds of mining and energy companies, as well as investors who are focused on the mining and energy sectors.

Mr. Rani Jarkas will be sharing his extensive experience and profound insights, as well as Cedrus' expertise in investing in the clean technology and energy sectors.

Mr. Rani Jarkas said, "China is now committed to building a greener energy system to meet spiking energy demand while protecting the environment and improving public health by reducing emissions. As development priority is being granted to the clean energy sector, we expect the amount of investment being deployed to the sector to escalate in the coming years. With coal being the major energy source in China currently, we believe the switch to building a clean, low-carbon, safe and efficient modern energy system will certainly bring immense opportunities to investors."

"Cedrus' goal is to identify and capture these investment opportunities and make them financially rewarding to our clients, while making contributions to the development of this promising sector that benefits the global environment overall." Mr. Rani Jarkas added.

About Cedrus Investments
Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

SOURCE Cedrus Investments

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Hong Kong, China -- (SBWIRE) -- 11/19/2017 -- Cedrus Investments ("Cedrus"), a global boutique investment firm, will host a life sciences luncheon on Tuesday, November 7th, 2017 in Beijing at the Shangri-La China World Summit Wing Hotel. Mr. Randy Hice, Cedrus' Chief Technical Officer and Member of the Life Sciences Advisory Board, will be sharing his insights on two critical themes in biotechnology: "New Frontiers in Immunology R&D" and "Increasing Laboratory Productivity and Meeting FDA Compliance through Software".

Mr. Hice is recognized worldwide as a leading authority in laboratory informatics and the most published author in the world on topics of complex laboratory automation and workflow analysis. His recent positions included the CEO of Laboratory Expertise Center, Inc. and Manager of Global Strategy at Abbott Informatics, a division of Abbott Laboratories.

This is the second year that Cedrus will hold such life sciences luncheon series in China, after a successful kick-off in Shanghai last year which brought together leading institutional investors, venture capitalists, and company executives. Cedrus views it as a strategic program that bridges the Chinese life sciences community with the rest of the world by offering cutting-edge and professional opinions with far-reaching influences.

Cedrus' Chairman, Mr. Rani Jarkas said, "The goals of Cedrus holding such events are to share the latest, timely and strategic industry information, uncovering unique investment opportunities and bringing together industry leaders for networking. The feedback from participants of last year's luncheon was very positive, as the event provided elite investors with the information that helped them establish an in-depth and sophisticated way of thinking when making their investment decisions. Thus, Cedrus will keep on offering such opportunities in the future as long as they benefit our clients and investors alike."

About Cedrus Investments
Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

SOURCE: Cedrus Investments

For further information about Cedrus Investments, please visit http://www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Hong Kong, China -- (SBWIRE) -- 11/19/2017 -- The Chairman of Cedrus Investments ("Cedrus"), Mr. Rani Jarkas, is invited to speak at the 121 Mining Investment Hong Kong 2017 – Spring Edition conference to be held on 29th – 30th of March 2017 in Hong Kong. Participants of the conference include senior executives from leading investment firms and mining companies.

Mr. Rani Jarkas' panel discussion will focus on the "state of Hong Kong as a mine finance destination." He will be sharing Cedrus' decades of experience and insights in investing in the mining and natural resources sectors.

Mr. Rani Jarkas said, "I am honored to join the panel discussion. Today, the mining sector around the globe is experiencing an irreversible and sustained tide of revolution driven by the advancements in modern technology and the transformation of energy sourcing for the purpose of building an efficient, greener energy system."

With the economic recovery worldwide picking up steam and developing countries' growth showing early signs of reacceleration, the potential of the mining industry overall is promising. In order to grasp the opportunities that lie ahead, we will need not only great minds, but also consistent funding support from visionary investors. Cedrus, with decades of experience operating globally, including in Hong Kong, is willing to further explore the city's unique geographical and free capital flows advantages as well as being a major global financial hub in fueling the sector's revolutionary progress, and help investors better invest in this sector potentially with higher degree of success," Mr. Rani Jarkas added.

About Cedrus Investments
Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

SOURCE: Cedrus Investments

For further information about Cedrus Investments, please visit http://www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Ms. Olivia Lam, Executive Director at Cedrus Investments (“Cedrus”), was one of the three keynote speakers at the “Australia Biotech Invest” held in Melbourne on October 24th, 2017.

Hong Kong, China -- (SBWIRE) -- 11/16/2017 -- Ms. Olivia Lam, Executive Director at Cedrus Investments ("Cedrus"), was one of the three keynote speakers at the "Australia Biotech Invest" held in Melbourne on October 24th, 2017. This annual event organized by AusBiotech, an Australian life sciences organization, attracted over 300 company executives in the industry and investors around the world attending this year. The Biotech Invest series, which also includes an annual investment conference in Hong Kong, has recently been expanded to Singapore and Shanghai in response to the rapidly-growing appetite for life sciences investments in Asia and the Greater China region. Since its inaugural conference in Hong Kong in 2013, Cedrus has been working closely with AusBiotech to foster investments in the life sciences industry across borders.

Ms. Lam's presentation was focused on the opportunities and challenges encountered by Australian life sciences firms in raising capital, and forming partnerships and joint ventures with their counterparts or investors in the Greater China region. She also spoke about the usual structures of cross-border life sciences transactions and their respective advantages and disadvantages.

In recent years, Cedrus has been actively engaged in assisting life science companies from Australia and Europe to gain access to the Chinese market through private placements, identifying potential strategic business partners and investors, structuring and negotiating cross-border collaborations as well as setting up joint ventures.

Cedrus' Chairman, Mr. Rani Jarkas said, "We have seen growing interest from Chinese enterprises and investors to acquire life sciences technologies and products overseas, and the increased desire of Australian life science companies to build a presence in China, the second-largest biopharma market in the world. Through facilitating various deals, we have accumulated a lot of expertise and valuable experience in cross-border transactions and collaborations. We are happy to share them with investors and company executives, helping them achieve their strategic goals."

About Cedrus Investments
Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

SOURCE Cedrus Investments

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm